Yongin, South Korea – September 10, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, served as a Platinum Sponsor at the Asia Bio Partnering Forum 2026 (ABP 2026) in Singapore, held from August 31 to September 2, as it pursued expansion of its assay development and sample analysis services across the Asia-Pacific region.
ABP 2026 drew 650 industry professionals and 2,500 one-on-one partnering meetings
The forum brought together approximately 650 pharmaceutical and biotechnology executives, investors and life sciences stakeholders, with roughly 2,500 one-on-one partnering meetings held over three days. GCCL used the event to hold discussions with drug developers, contract research organizations (CROs) and regional stakeholders from Korea, China, Japan, Singapore, Vietnam and Europe.
GCCL targets developers of mRNA, radiopharmaceutical and antibody-based therapies
The company engaged with drug developers working across mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies, focusing talks on evolving analytical requirements tied to these modalities. GCCL also met with global CRO executives and Singapore-based pharmaceutical, diagnostics and clinical trial service companies to review existing partnerships and identify further collaboration.
Company held talks with a Singapore government-affiliated economic development body
GCCL engaged with a Singapore government-affiliated economic development organization to discuss support mechanisms for local biotech companies and stronger ties within the regional life sciences ecosystem.
GCCL sponsored the official ABP 2026 Welcome Reception
As Platinum Sponsor, GCCL backed the event's official Welcome Reception, where Yoo-Hwa Choi, Head of Business Operations at GCCL, delivered welcome remarks outlining the company's clinical sample analysis capabilities and its role in global drug development support.
Exhibition booth showcased integrated Central Lab, Bioanalytical Lab and R&D Lab operations
At its booth, GCCL presented its integrated Central Lab, Bioanalytical Lab and R&D Lab capabilities, which the company says support clinical development from early-stage through late-stage trials. "ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities," Choi said.